GlassScriptPhysician profile
Deanna Willyerd
NPI 1578178943
$2,440.99
in general payments reported to CMS, 2019-2025
22 companies · $505 in 2025
The $505 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $126 · 2022: $425 · 2023: $671 · 2024: $714 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,890.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $473.61 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $404.51 | 2022-2025 | |
| Novo Nordisk INC | $273.96 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $239.66 | 2021-2025 | Mounjaro, Zepbound |
| Daiichi Sankyo INC. | $223.33 | 2023-2025 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.03 | 2022 | |
| Abbvie INC. | $131.50 | 2022-2025 | |
| Exact Sciences Corporation | $80.68 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $71.57 | 2024-2025 | Evenity, Prolia, Prolia |
| Regeneron Healthcare Solutions, INC. | $59.95 | 2023 | Evkeeza |
| Pfizer INC. | $55.31 | 2022-2025 | |
| Dexcom, INC. | $55.07 | 2024-2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $37.54 | 2024 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $33.90 | 2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.16 | 2022-2024 | Xifaxan |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $32.66 | 2024-2025 | Mcot, (Ck4) Mcot |
| Sk Life Science, INC. | $20.20 | 2021 | |
| Xeris Pharmaceuticals, INC. | $19.95 | 2023 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $18.58 | 2025 | Rexulti |
| Amarin Pharma, INC. | $14.66 | 2023 | |
| Currax Pharmaceuticals LLC | $13.76 | 2023 | Contrave, Onzetra Xsail, Nexlizet |
| Glaxosmithkline, LLC. | $13.40 | 2023 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deanna Willyerd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.